Back to results
US 2013/0230902 A2Published application
Chimeric adenoviruses for use in cancer treatment
AssigneePsioxus Therapeutics Limited
InventorsPaul HARDEN, Terry HERMISTON, Irene KUHN
Life of this patent
Estimating the term…
Abstract
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Claims8
A chimeric adenovirus having a genome comprising an E2B region, wherein:
- said E2B region comprises a nucleic acid sequence derived from a first adenoviral serotype and a nucleic acid sequence derived from a second adenoviral serotype;
- said first and second serotypes are each selected from the adenoviral subgroups B, C, D, E, or F and are distinct from each other;
- and
- said chimeric adenovirus is oncolytic and demonstrates an enhanced therapeutic index for a tumor cell.
1 more element
A chimeric adenovirus having a genome comprising an E2B region, and regions encoding a fibre, hexon and penton proteins, wherein:
- said E2B region comprises a nucleic sequence derived from a first adenoviral serotype and a second adenovirus serotype each independently selected from subgroup B and which are distinct from each other, and
- the nucleic acids encoding fibre, hexon and penton proteins are all from the same adenovirus serotype, namely Ad11, and
- said chimeric adenovirus or variant or derivative thereof is oncolytic and demonstrates an enhanced index for a tumor cell.
Dependencies are inferred from the claim text.